Brookstone Capital Management Reduces Stock Holdings in CVS Health Corporation $CVS

Posted by Geri Gentry on Jun 25th, 2026

Brookstone Capital Management lowered its holdings in CVS Health Corporation (NYSE:CVS – Free Report) by 15.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,368 shares of the pharmacy operator’s stock after selling 5,746 shares during the quarter. Brookstone Capital Management’s holdings in CVS Health were worth $2,181,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CVS. Sei Investments Co. grew its position in shares of CVS Health by 17.4% during the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after acquiring an additional 134,535 shares during the period. The Manufacturers Life Insurance Company boosted its position in CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina boosted its position in CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after purchasing an additional 7,588 shares in the last quarter. HUB Investment Partners LLC grew its holdings in CVS Health by 25.0% in the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after purchasing an additional 3,011 shares during the period. Finally, Alliancebernstein L.P. increased its position in shares of CVS Health by 8.0% in the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after buying an additional 119,439 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CVS shares. Wells Fargo & Company increased their target price on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Mizuho boosted their price target on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Bank of America upped their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. Finally, UBS Group boosted their target price on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $101.28.

Get Our Latest Stock Analysis on CVS Health

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: CVS is expanding its direct-to-consumer GLP-1 weight-loss program and stepping up support for GLP-1 customers, which could open a new revenue stream and deepen its consumer health business. CVS expands direct-to-consumer GLP-1 weight-loss program
Positive Sentiment: CVS also continues to get attention from investors and value-focused analysts, which can support sentiment around the stock. CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
Neutral Sentiment: Coverage noting CVS as a top-ranked value stock may reinforce the company’s defensive appeal, but it does not appear to be a major new catalyst on its own. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
Neutral Sentiment: CVS’s community and health-awareness announcements, including an HIV-awareness message and a New Jersey grand opening, are supportive of brand image but are unlikely to materially move the stock. Why CVS Stock Trounced the Market Today
Negative Sentiment: Florida’s attorney general subpoenaed CVS Health and launched an investigation into alleged anticompetitive pharmacy practices, adding legal and regulatory overhang. Florida Attorney General Issues Subpoena to CVS Health in Pharmacy Probe
Negative Sentiment: Related reports about the Florida AG probe and alleged anticompetitive behavior reinforce concern that CVS could face scrutiny, legal costs, or operational changes. Florida AG to probe CVS for anticompetitive pharmacy practices

CVS Health Stock Up 0.5%

NYSE CVS opened at $102.04 on Thursday. The business has a fifty day moving average price of $90.69 and a 200 day moving average price of $82.04. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market cap of $130.19 billion, a P/E ratio of 44.95, a P/E/G ratio of 0.99 and a beta of 0.62. CVS Health Corporation has a one year low of $58.50 and a one year high of $103.12.

CVS Health (NYSE:CVS – Get Free Report) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.